Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
January 2, 2018
Vericel Corporation (VCEL initiated a License Agreement with Innovative Cellular Therapeutics (ICT)
December 29, 2017
RegMed Investors’ (RMi) closing bell; what’s pulling the sector along
December 19, 2017
RegMed Investors’ (RMi) closing bell; Sector opened up and slid to the downside at the close
December 11, 2017
RegMed Investors’ (RMi) closing bell; ASH giveth and taketh
December 8, 2017
RegMed Investors’ (RMi) closing bell; the newest version of an old normal
December 7, 2017
RegMed Investors’ (RMi) closing bell; finally an upside
December 6, 2017
RegMed Investors’ (RMi) closing bell; another day of woe to a cell therapy portfolio
December 6, 2017
RegMed Investors’ (RMi) closing bell; another day of woe to a cell therapy portfolio
December 6, 2017
RegMed Investors’ (RMi) pre-open indication: investors have a right to know
December 5, 2017
RegMed Investors’ (RMi) closing bell; today’s a tug of war of pricing and value
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.